What the science actually says about Mochi Health (and the GLP-1 programs competing for your money)

By Sumaia · Last reviewed June 2025 · 9 min read

Mochi Health’s pitch is straightforward: pay a monthly membership, get matched with a provider, and walk away with a GLP-1 prescription. The platform has grown fast enough to attract real media attention. But “fast-growing” and “clinically sound” aren’t the same thing. Here’s what the actual trial data says about the drugs these programs prescribe, and what the programs themselves do and don’t give you.

Does the science behind GLP-1 medications actually support the weight loss claims?

Yes, and the effect sizes are larger than almost anyone expected a decade ago. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) put 1,961 adults on 2.4mg weekly semaglutide versus placebo for 68 weeks. The semaglutide group lost 14.9% of body weight on average. The placebo group lost 2.4%. That’s not a rounding error, it’s a different drug class than anything that came before it.

Tirzepatide numbers are even higher. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) randomized 2,539 adults to tirzepatide at 5mg, 10mg, or 15mg weekly, or placebo, for 72 weeks. At the 15mg dose, participants lost 20.9% of body weight. At 5mg, still 15.0%. The placebo group lost 3.1%. These are the drugs that programs like Mochi, Noom Med, and others are prescribing or facilitating access to.

The mechanism matters here. Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, suppresses appetite through hypothalamic signaling, and reduces the reward response to food. Tirzepatide adds GIP receptor agonism on top of that, which appears to drive the additional weight loss seen in SURMOUNT.

What does Mochi Health actually offer, and how does it compare to other platforms?

Mochi Health is a telehealth platform that connects patients with licensed providers who can prescribe GLP-1 medications, including brand-name Ozempic, Wegovy, and compounded versions when brand supply is constrained. They charge a membership fee (around $99/month as of early 2025) on top of medication costs. You fill out intake forms, have an async or video visit, and if you qualify, get a prescription.

Noom originally built its brand around behavioral psychology and calorie tracking. Noom Med, its prescription arm, added GLP-1 prescribing to that behavioral layer. The idea is that medication plus the habit-change curriculum produces better long-term outcomes than either alone. That’s a reasonable hypothesis. The data supporting Noom’s specific program is much thinner than the clinical trial data behind the drugs themselves.

Orderly Meds is a smaller player in the same space, focused on compounded semaglutide access at lower price points. The value proposition is similar to what drew me to a compounded GLP-1 service: brand-name GLP-1s are priced out of reach for most people without insurance coverage, and compounded versions from 503B-licensed pharmacies use the same active pharmaceutical ingredient.

The honest comparison is in the table below.

Platform Monthly membership Medication source Behavioral coaching 503B pharmacy access Mochi Health ~$99 Brand + compounded Limited Yes (when offered) Noom Med ~$69-$99 Brand + compounded Yes (Noom curriculum) Varies Orderly Meds ~$49-$79 Compounded focus Minimal Yes FormBlends Included in med cost Compounded (503B) Async provider support Yes

Prices fluctuate. Treat this as a directional comparison, not a quote.

Is compounded semaglutide the same drug as Ozempic or Wegovy?

It contains the same active ingredient. It’s not the same product. That distinction matters legally and clinically.

Brand-name Ozempic and Wegovy are FDA-approved drug products manufactured by Novo Nordisk. Compounded semaglutide is produced by 503A or 503B pharmacies under FDA oversight but without the same approval pathway. The FDA has stated clearly that compounded drugs are not FDA-approved and don’t have the same safety and efficacy data as approved products. That’s the accurate regulatory framing.

What 503B pharmacies do is manufacture non-patient-specific batches under current Good Manufacturing Practice standards. That’s meaningfully different from a 503A compounding pharmacy mixing up individual prescriptions in the back of a retail pharmacy. I use a 503B-sourced provider specifically because of that manufacturing rigor.

The practical reality for most patients is that brand-name GLP-1s run $900-$1,300/month without insurance. Compounded versions through platforms like compounded GLP-1 providers run $150-$350/month for similar doses. For the 70–80% of patients whose insurance denies GLP-1 coverage (a figure Novo Nordisk has cited in investor calls), compounded is the only path that doesn’t require going into debt.

What does the STEP and SURMOUNT data actually tell us about long-term outcomes?

The trials show real, substantial weight loss. They also show a well-documented rebound when medication stops.

The STEP 4 trial (Rubino et al., NEJM, 2021) is the key reference here. Participants who lost weight on semaglutide over 20 weeks were then randomized to continue semaglutide or switch to placebo for another 48 weeks. The placebo group regained two-thirds of their lost weight. The semaglutide group continued losing, down to 17.4% total loss. The message is not subtle: the drug works while you take it.

This is the core tension in every GLP-1 telehealth program. The clinical evidence is strong. The question is whether these platforms support patients through the parts that are actually hard: the first 4–8 weeks of nausea, the insurance appeals, the dose titration that takes months to complete, and the long-term maintenance question.

Mochi and Noom both advertise provider access, but the real-world experience of patients on forums like r/Semaglutide and r/WegovyWeightLoss suggests async messaging with a response lag of 24–72 hours is common across all telehealth platforms. That’s not a Mochi-specific problem, it’s a structural feature of the telehealth model.

For what it’s worth: I had one bad month of nausea at 0.5mg that I managed with ginger tea and meal timing, with no urgent care visits. I didn’t need same-day provider access. Most people don’t. But the patients who do need it should know what they’re signing up for.

Does adding behavioral coaching to GLP-1 medication improve outcomes?

Probably yes, but the magnitude is unclear and the evidence base for specific programs is weak.

The STEP 5 trial (Garvey et al., Nature Medicine, 2022) ran semaglutide plus lifestyle intervention versus placebo plus lifestyle intervention for 104 weeks (2 years), with 304 participants. The semaglutide group lost 15.2% of body weight versus 2.6% in the placebo group. Both groups received intensive behavioral counseling. The lifestyle component was standardized and fairly intensive, not a digital curriculum.

Whether Noom’s specific app-based behavioral program matches that level of intervention is unknown. Noom published its own study (Funk et al., Scientific Reports, 2020) showing weight loss in app users, but it was an observational study of 35,921 users without a randomized control group, which limits what you can conclude. To their credit, they’ve been transparent about that.

The honest answer is that the best behavioral support for GLP-1 users is probably individualized nutrition guidance and regular provider check-ins. Most telehealth platforms deliver that imperfectly. If you’re choosing between platforms primarily on the behavioral coaching angle, I’d want to see peer-reviewed evidence before paying a premium for it.

What are the real risks of using a telehealth GLP-1 platform?

The drug risks are well-characterized. The platform risks are less discussed.

On the drug side, the most common side effects in STEP 1 were nausea (44% of semaglutide patients vs. 16% placebo), diarrhea (30% vs. 16%), and vomiting (24% vs. 6%). These are mostly dose-dependent and front-loaded in the first 8–12 weeks. Serious adverse events were similar between groups. The FDA label for semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies; the clinical significance in humans is not established, but people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use it.

On the platform side, the risks are less about safety and more about continuity. Telehealth prescribers vary in their responsiveness and clinical judgment. Some platforms have faced scrutiny over prescribing practices when the FDA tightened compounding rules during the semaglutide shortage. When the FDA removed semaglutide from the shortage list in early 2025, several compounding platforms had to rapidly restructure their offerings. Patients in the middle of treatment were disrupted.

Choosing a compounded GLP-1 provider that sources from a 503B-licensed pharmacy and has clear policies around prescription continuity matters more than it sounds when you’re six months into treatment and have found your maintenance dose.

Frequently asked questions

Is Mochi Health legitimate?

Mochi Health is a licensed telehealth platform that employs or contracts with licensed medical providers. It’s not a scam. Whether it’s the right fit depends on your insurance situation, your need for behavioral support, and how much you want to pay for the membership layer on top of medication costs.

How does Mochi Health’s pricing compare to brand-name GLP-1 costs?

Brand-name Wegovy lists at around $1,350/month without insurance. Mochi’s membership is roughly $99/month, but you still pay for the medication separately. If they prescribe brand-name, you’re looking at $1,400+ total. If they prescribe compounded, costs drop substantially, often to $200-$400/month depending on dose.

What does the FDA say about compounded semaglutide?

The FDA has stated that compounded drugs are not FDA-approved and that 503B outsourcing facilities may only compound drugs that appear on the FDA’s shortage list or meet other specific conditions. As of early 2025, the FDA removed semaglutide from the shortage list, which has created regulatory uncertainty for compounding platforms. Check current FDA guidance before starting.

Does Noom Med work better than Mochi for long-term weight loss?

There’s no head-to-head trial comparing Noom Med to Mochi Health. Both prescribe the same medications. The difference is Noom’s behavioral curriculum, which has some observational evidence but no randomized trial data proving it improves outcomes versus GLP-1 alone in a telehealth context.

What is a 503B pharmacy and why does it matter?

A 503B outsourcing facility is FDA-registered and manufactures drug products under Good Manufacturing Practice standards without patient-specific prescriptions. This is a higher standard than a 503A compounding pharmacy. If you’re using compounded semaglutide, sourcing from a 503B facility provides more manufacturing oversight than the alternative.

What happened during the semaglutide shortage, and is it over?

The FDA added semaglutide to its drug shortage list in 2022, which allowed 503B pharmacies to compound it legally in larger volumes. Novo Nordisk increased manufacturing capacity, and the FDA removed semaglutide from the shortage list in February 2025. This created a legal gray area for ongoing compounding. The situation is still evolving and worth monitoring if you’re currently on compounded semaglutide.

How much weight loss is realistic on semaglutide or tirzepatide?

The STEP 1 trial (Wilding et al., NEJM, 2021) showed average weight loss of 14.9% at 68 weeks on 2.4mg semaglutide. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) showed 20.9% at 72 weeks on 15mg tirzepatide. Individual results vary based on genetics, diet, adherence, and dose achieved. I’m down 38 pounds at six months, which is roughly in line with the trial averages at this point in treatment.